The duration of
potential vaccine virus transmission may vary.
Not exact matches
«Persons who have already completed the hepatitis A
vaccine series are not at risk of developing hepatitis A
virus infection from this
potential exposure.»
The epitope where 2D22 binds to the
virus may therefore represent a
potential vaccine target.
Roughly a year after Brazilian doctors and researchers first suspected a link between a spate of alarming birth defects and the Zika
virus, a cadre of
potential vaccines are now headed for testing in humans.
Contributing to work on smallpox, polio, and
vaccine development, primates allow research on
potential treatments for hepatitis C and B, Ebola and Marburg
viruses, and HIV / AIDS.
VLP
vaccines often prompt an immune reaction similar to that of natural, whole
virus and have a number of
potential advantages over traditional
vaccines, said Dr. Ledgerwood.
Live
virus vaccines have serious
potential drawbacks, though, including harmful infection with the
virus in people who have weakened immune systems.
The lack of a
vaccine or antiviral drugs to combat the Zika
virus has scientists scrambling to identify and better characterize
potential drug targets.
The
vaccines targeted an influenza A H1N1 seasonal flu strain as well as A (H7N9), a
virus considered to have the
potential to trigger a human pandemic.
The
vaccine significantly reduced
virus excretion, which should help reduce the
potential for transmission to humans, and conferred cross-immunity to camelpox infections.
As a final confirmation of the compound's
potential to stop a
virus from spreading, they tested it against an actual
virus: the nonpathogenic
vaccine strain of the Junin
virus.
Kang's primary research focuses on designing and developing effective
vaccines against viral diseases such as influenza
virus and RSV, but he partnered with a university and research institutes in South Korea that wanted international collaborative projects to study if ginseng can be used to improve health and protect against disease because of the
potential benefit in fighting these
viruses.
Unlike other candidates, a new
potential Zika
vaccine is so effective that one shot gives enough protection — a key advance, given the
virus is here to stay
«We discovered that there was a lot of naturally occurring resistance, meaning we may need to greatly expand the set of
viruses we use to evaluate
potential vaccines,» says Ramy El - Diwany, a student at the Johns Hopkins University School of Medicine and first author of the study.
But many governments have stockpiled
vaccine in case bioterrorists get their hands on a
potential hidden cache of the
virus.
Their study found «a
potential link between the H1N1
virus used to make the
vaccine and narcolepsy.»
Instead of a liquid containing whole killed or attenuated
virus, this
vaccine uses dry
virus - like particles (VLPs) which simply coat the needles in the presence of a simple stabilizing agent, reducing the need for refrigeration — a
potential boon for use in developing countries.
We hope that in the future this discovery could lead to ways of generating
potential Zika
virus vaccines.»
«It's data that everyone that's studying these coronaviruses has been waiting on,» says Matthew Frieman, a microbiologist at the University of Maryland in Baltimore who is developing a
potential vaccine for the
virus.
Infection of mice with these
viruses has been successfully applied to study aspects of HIV neuropathogenesis and to evaluate antiretroviral drugs and
potential HIV
vaccines.
«Advances toward
potential Zika
virus vaccine development.»
Late last week, FDA worked with the United States Attorney to ask a court to seize the components of a product that involved the use of vaccinia
virus vaccine as part of a purported treatment for cancer that FDA believes created the
potential for substantial risks to patients.
While studying a group of women at risk of HIV in Mombasa, Kenya, Dr. Julie Overbaugh and colleagues found a
potential vulnerability in the AIDS
virus that could lead to clues for designing an effective
vaccine.
A study published in Nature reports the results of trials of two
potential vaccines against the Zika
virus in mice.
The
potential new
vaccine, invented at Georgia Tech, employs a fake
virus as bait to attract major immune system forces to these weaknesses to attack them.
The Delta VP30 technology has been approved by the National Institutes of Health for use under Biosafety Level 2 conditions and has been utilized safely for a decade to study the basic biology of the
virus, identify
potential antiviral compound candidates, and make the whole -
virus vaccine.
Last Wednesday, U.S. health officials announced that a
potential vaccine for the Zika
virus had entered early clinical trials to assess its safety in humans.
In other news, research on a
potential vaccine for the Zika
virus entered early clinical trials last week.
In the DVM round table discussion mentioned earlier, Dr Rude asked whether the shedding of modified live
virus vaccine viruses from vaccinated animals have the
potential to cause disease in non-vaccinated contact animals of the same species and / or different species.
However, if the
vaccine has the
potential to sensitize cats to enhanced disease as suggested by the Cornell studies, it may not be appropriate to use it under conditions where exposure to high concentrations of infectious
virus is likely.
«The new technology offers the
potential for faster start - up of the
vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza
virus.»